Delivery Order SPE2DB25D3017-SPE2DB25FVKBL
- Not listed
- The Defense Logistics Agency awarded a $13,451.77 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed price contract has a completion date of July 31, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,216.66 on August 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, with performance conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with a ceiling value of $18,294.14. This competitively awarded, firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $12,166.39. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of April 25, 2025. This delivery order is...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a firm fixed price ceiling value of $39,510.41. This non-set-aside competitive award is structured as a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials with a ceiling value of $15,480.98. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $8,168.32 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed-price delivery order has a ceiling value of $9,330.09 with an ultimate completion date of August 6, 2025. The pharmaceutical product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, serving federal defense and military healthcare...
- The Defense Logistics Agency awarded a $5,877.92 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This competitive award, which carries a firm fixed price structure and an ultimate completion date of September 19, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract involves no set-aside designation and specifies...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with a contract ceiling value of $5,639.94 and an ultimate completion date of July 14, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical...
- SPE2DB25D3017Indefinite Delivery Contract
- SPE2DB25D3017-SPE2DB25FVKBLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a contract ceiling value of $34,924.93. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 million prime vendor agreement running through December 2026 that supports global pharmaceutical supply needs for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency and military healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to meet competitive procurement requirements across a diverse range of pharmaceutical products and medical supplies, including specialty medications, vaccines, and medical devices. This specific delivery order for Ozempic, a diabetes management medication, reflects the company's ongoing role in supplying essential medications to support military and veteran healthcare needs through the DLA's comprehensive pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $34.9k | 7/31/25 |